Stockwatch: The Blockbuster Delusion
This article was originally published in Scrip
Executive Summary
Last week was one of changing fortunes as companies reported their first-quarter financial results. For a few days, the gloom of the previous week was lifted by the effects of growing sales of blockbuster products from Amgen and Roche by virtue of limited or in spite of exposure to the euro, respectively. However, by the end of last week we were back to doom and gloom again.